Full-Time

Sr. Director

Business Operations Leader

Confirmed live in the last 24 hours

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Biotechnology
Healthcare

Compensation Overview

$253k - $271kAnnually

+ Equity Component

Expert

San Carlos, CA, USA

Hybrid position.

Category
Project Management
Business Development
Business & Strategy

You match the following Vaxcyte's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • BA/BS required with MBA or relevant advanced degree highly desired.
  • A minimum of 15 years’ experience in pharmaceutical or biotechnology industry, with significant expertise in commercialization product strategy, lifecycle management, and business operations.
  • Able to quickly establish credibility and build trusting relationships across functions, and with partners and stakeholders.
  • Strong organizational, management, and collaboration skills, with proven ability to facilitate strategic initiatives and align diverse teams towards common goals while managing multiple priorities and delivering results.
  • Excellent communication and presentation skills; able to simplify complex concepts and convey effectively to diverse audiences, including executives and key stakeholders.
  • Experience in developing phase-appropriate strategies and risk management across all stages of drug development and lifecycle management.
  • Experience with portfolio management, prioritization, and data-driven decision making.
  • Experience with operational excellence principles and applications based on SixSigma, Lean, Kaizen, or TQM frameworks.
  • Knowledge of global regulatory compliance requirements for biologics is preferred and prior experience with manufacturing operations for vaccines is beneficial.
Responsibilities
  • Establish foundation of cross-functional working norms for CMSC to enable organizational effectiveness, timely deliverables, and inform decision making across the organization.
  • Work across CMSC to develop a multi-year Capabilities Roadmap that represents our strategic vision to meet the needs of the business with the overarching goal of reducing complexity and driving operational efficiencies.
  • Develops tools and business processes to identify, prioritize and manage oversight of strategic projects in CMSC that are building current and/or future capabilities.
  • Facilitate annual budget and LRP (Long Range Planning) processes that are aligned with the organizational strategy and incorporate appropriate risk profile.
  • Establish and maintain key CMSC business operations cadence of corporate processes for goal setting, performance metrics, and talent management.
  • Develop tools and business processes that enable cohesive strategies across product teams with inputs from Manufacturing, MSAT, Supply Chain, Process Development, Regulatory and Quality and outputs that can be governed.
  • Facilitate global team interactions, cross-functional communication, and address changes in program or project risk profiles with an appropriate sense of urgency.
  • Champion collaborative and growth mindsets that foster continuous improvement and enhance quality, efficiency and performance across CMSC.
  • Support organizational change management efforts and guide leaders through transformations needed for process improvements, technology adoption, and anticipated scaling to ensure successful implementation and team buy-in.
  • Onboard and train staff on CMSC structure and expectations for working with key external partners, vendors, and stakeholders so that they can clearly convey CMSC goals and engage in collaborations with mutual benefit.
Desired Qualifications
  • Knowledge of global regulatory compliance requirements for biologics is preferred and prior experience with manufacturing operations for vaccines is beneficial.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA. Vaxcyte utilizes advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while stimulating an immune response. This method sets them apart from traditional cell-based vaccine production. The company's goal is to develop and commercialize broad-spectrum vaccines to improve global health outcomes, particularly for vulnerable populations.

Company Stage

IPO

Total Funding

$273.3M

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

2%

1 year growth

2%

2 year growth

1%
Simplify Jobs

Simplify's Take

What believers are saying

  • FDA Breakthrough Therapy designation for VAX-24 may accelerate its market entry.
  • Global pneumococcal vaccines market is projected to grow at a CAGR of 5.6% until 2030.
  • Recent $1.5 billion public offering strengthens Vaxcyte's financial position for future developments.

What critics are saying

  • Competition from mRNA technology developers like Moderna and BioNTech is intense.
  • Potential regulatory delays could impact Vaxcyte's clinical trial timelines.
  • Intellectual property disputes may arise over cell-free protein synthesis technology.

What makes Vaxcyte unique

  • Vaxcyte uses a proprietary cell-free protein synthesis platform, XpressCF™, for vaccine development.
  • Their lead product, VAX-24, targets 24 strains of Streptococcus pneumoniae bacteria.
  • Vaxcyte focuses on broad-spectrum vaccines for bacterial infections, unlike traditional methods.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Stock Options

Remote Work Options